Tofogliflozin: First Global Approval
- 22 May 2014
- journal article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 74 (8), 939-944
- https://doi.org/10.1007/s40265-014-0229-1
Abstract
Tofogliflozin (Apleway®, Deberza® [Japan]), an orally active small molecule sodium-glucose co-transporter type 2 (SGLT2) inhibitor, has been developed by Chugai Pharmaceutical for the treatment of type 2 diabetes mellitus (T2DM), and a marketing authorization application was filed in Japan in 2013 by licensees Sanofi K.K. and Kowa. Tofogliflozin has received its first global approval for this indication in Japan as either monotherapy or in combination with other antihyperglcaemic agents. This article summarizes the milestones in the development of tofogliflozin leading to this first approval for the treatment of T2DM.Keywords
This publication has 17 references indexed in Scilit:
- SGLT-2 inhibitors and their potential in the treatment of diabetesDiabetes, Metabolic Syndrome and Obesity, 2013
- Tofogliflozin, a novel sodium–glucose co‐transporter 2 inhibitor, improves renal and pancreatic function in db/db miceBritish Journal of Pharmacology, 2013
- Sodium–glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitusDiabetes/Metabolism Research and Reviews, 2013
- Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitusExpert Opinion on Investigational Drugs, 2013
- Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2013
- In Vitro–In Vivo Correlation of the Inhibition Potency of Sodium-Glucose Cotransporter Inhibitors in Rat: A Pharmacokinetic and Pharmacodynamic Modeling ApproachJournal of Pharmacology and Experimental Therapeutics, 2013
- Comment on: Vila et al. B-Type Natriuretic Peptide Modulates Ghrelin, Hunger, and Satiety in Healthy Men. Diabetes 2012;61:2592–2596Diabetes, 2012
- Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?Diabetes, 2012
- SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitusJournal of Pharmacy and Pharmacology, 2012
- Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and MiceJournal of Pharmacology and Experimental Therapeutics, 2012